Implications of Serum Cholesterol Measurement for the Vascular Surgeon

Abstract

Objective: To measure the serum total cholesterol in new patients with intermittent claudication and to assess the proportion with ischemic heart disease and untreated hypercholesterolemia.

Design: A prospective study with patient history corroborated by a general practitioner telephone questionnaire.

Setting: A vascular surgical center in a major teaching hospital.

Subjects: Seventy-six consecutive claudicants were studied (median age, 66; range, 46 to 94; 45 men and 31 women), of whom 41 (54%) had ischemic heart disease.

Results: The median serum total cholesterol concentration was 6.35 mmol/L (IQR, 5.60 to 7.05 mmol/L). Forty-nine (65%) patients had never had their serum cholesterol assayed before this study despite 24 of them having ischemic heart disease.

Conclusions: Previously undiagnosed hypercholesterolemia is commonly revealed in the vascular surgical assessment of patients with intermittent claudication. The cardiac morbidity and mortality of these patients is high and surgeons should therefore be proactive in the instigation of cholesterol-lowering therapy.

Get full access to this article

View all access options for this article.

References

1. Kannel WB McGee DL : Update on some epidemiological features of intermittent claudication. J Am Geriatr Soc 33:13-18, 1985.

2. Widmer LK , Biland L : Incidence and course of occlusive peripheral arterial disease in geriatric patients: Possibilities and limits of prevention. Int Angiol 4:289-294, 1985.

3. Hertzer NR , Beven EG , Young JR , et al: Coronary artery disease in peripheral vascular patients. Ann Surg 199:223-233, 1984.

4. Gotto A Jr , LaRosa JC , Hunninghake D , et al: The cholesterol facts: A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation 81:1721-1733, 1990.

5. Duffield RGM , Miller NE , Brunt JNH , et al: Treatment of hyperlipidemia retards progression of symptomatic femoral atherosclerosis. Lancet 2:639-642, 1983.

6. Scandinavian Simvastatin Survival Group : Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383 1389, 1994.

7. Rutherford RB , Flanigan PD , Gupta SK , et al: Suggested standards for reports dealing with lower extremity ischemia. J Vasc Surg 4:80-94, 1986.

8. Parkin A , Wiggins PA , Robinson PJ , et al: The use of a gamma camera for limb blood flow measurements in peripheral vascular disease. Br J Surg 74:271-274, 1987.

9. Sacks FM , Pfeffer MA , Moye LA , et al: The effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996.

10.

10. Shepherd J , Cobbe SM , Ford I , et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307, 1995.

11.

11. Pharoah PD , Hollingworth W : Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: Life table method applied to health authority population. Br Med J 312:1443-1448, 1996.

12.

12. Daida H , Yokoi H , Miyano H , et al: Relation of saphenous vein graft obstruction to serum cholesterol levels. J Am Coll Cardiol 25:193-197, 1995.

13.

13. Glueck CJ : Role of risk factor management in progression and regression of coronary and femoral artery atherosclerosis. Am J Cardiol 57:35G-41G, 1986.

14.

14. Campeau L , Enjalbert M , Lesperance J , et al: The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: A study 10 years after aortocoronary bypass surgery. N Engl J Med 311:1329-1332, 1984.

15.

15. Palac RT , Meadows WR , Hwang MH , et al: Risk factors related to progressive narrowing in aortocoronary vein grafts studied 1 and 5 years after surgery. Circulation 66:140-144, 1982.

16.

16. Wiseman S. , Kenchington G , Dain R et al: Influence of smoking and plasma factors on patency of femoropopliteal vein grafts. Br Med J 299:643-646, 1989.